Hoffmann-La Roche Inc.

Roche Glycart Ag

Engmab Sarl

Bristol-Myers Squibb Compnay

Roche Palo Alto LLC

Roche Sequencing Solutions, Inc.

Roche Glyeart Ag

Engmab Ag

F. Hoffmann-La Roche Ag

Glycart Biotechnology Ag

Engmab Beta Holdings LLC

Ekkehard Moessner

Christian Klein

Pablo Umana

Ralf Hosse

Peter Bruenker

Thomas U Hofer

Anne Freimoser-Grundschober

Guy Georges

Marina Bacac

Oliver Ast

Claudia Ferrara Koller

Valeria G Nicolini

Tilman Schlothauer

Sandra Grau-Richards

Pablo Umaña

Michael Molhoj

Jens Niewoehner

Lydia Jasmin Hanisch

Tina Weinzierl

Joerg Thomas Regula

Maria Amann

Samuel Moser

Christina Claus

Viktor Levitski

Christiane Neumann

Tanja Fauti

Inja Waldhauer

Wolfgang Schaefer

Stefan Dengl

Hubert Kettenberger

Joerg Moelleken

Juergen Michael Schanzer

Thomas Emrich

Laurent Lariviere

Klaus Strein

Minh Diem Vu

Sylvia Herter

Olaf Mundigl

Birgit Bossenmaier

Stefan Klostermann

Wei Xu

Maximiliane Koenig

Adrian Hugenmatter

Ulrich Brinkmann

Ulrich Goepfert

Nikolaos Dimoudis

Fiona Grueninger

Claudio Sustmann

Wolfgang Richter

Johannes Sam

Anton Jochner

Kevin Brady

Alexander Knaupp

Diana Darowski

Halina Trochanowska

Stefan Seeber

Hans-Willi Krell

Jens Fischer

Eike Hoffmann

Valeria Lifke

Thomas Friess

Johannes Auer

Alexander Bujotzek

Rebecca Croasdale

Irene Kolm

Christian Jost

Linda Wicker

Laurence Bernard Peterson

Kay-Gunnar Stubenrauch

Sabine Imhof-Jung

Werner Scheuer

Petra Rueger

Georg Tiefenthaler

Joerg Benz

Gerhard Niederfellner

Huisheng Wang

Alexander Haas

Kathryn Elizabeth Packman

Barbara Weiser

Alexander Lifke

Valeria Runza

Lei Shi

Victor I Lyamichev

Peng Wang

Erhard Kopetzki

Jigar Patel

Manfred Kubbies

Frank Herting

Monika Baehner

Harald Duerr

Gang Xu

Stefan Jenewein

Rebecca Croasdale-Wood

Huifeng Niu

Hendrik Knoetgen

Roland Staack

Jan Olaf Stracke

Katharina Wartha

Joerg Zielonka

Francesca Ros

ANTI-HLA-G ANTIBODIES AND USE THEREOF

The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.

Methods of treating cancer by administering tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules

The present invention relates to trispecific antibodies binding to HER2 and a blood-brain barrier receptor (BBB-R), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Trispecific antibodies specific for HER2 and a blood brain barrier receptor and methods of use

The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.

Humanized anti-Tau(PS422) antibodies and methods of use

The present invention generally relates to antigen binding receptors capable of specific binding to mutated Fc domains with reduced Fc receptor binding and T cells expressing these antigen binding receptors. More precisely, the present invention relates to T cells, transfected/transduced with an antigen binding receptor which is recruited by specifically binding to/interacting with the mutated Fc domain of therapeutic antibodies. Furthermore, the invention relates to a kit comprising the T cells of the invention and/or nucleic acid molecules, vectors expressing antigen binding receptors of the present invention and (a) tumor targeting antibody/antibodies comprising a mutated Fc domain. The invention also provides the production and use of T cells in a method for the treatment of particular diseases in conjunction with tumor-specific antibodies as well as pharmaceutical compositions/medicaments comprising T cells and/or therapeutic antibodies, wherein T cells are to be administered in combination with therapeutic-tumor targeting antibody/antibodies comprising a mutated Fc domain with reduced Fc receptor binding.

Antigen binding receptors specific for mutated Fc domains

The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.

Anti-FAP antibodies and methods of use

The invention relates autonomous VH domains (aVH) with cysteines in positions 52a and 71 or in positions 33 and 52 in order to stabilize the autonomous VH domains. Said cysteines are capable of forming a disulfide bond and/or form a disulfide bond under suitable conditions. The invention further relates to aVH libraries.

Stabilized immunoglobulin domains

The present invention generally relates to antibodies that bind to CD3 and CD19, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Antibodies binding to CD3 and CD19

Herein is reported an antibody that specifically hinds to human CD 19, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 03, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 11, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 05, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 20 or 28, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 07, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 08, as well as methods of using the same.

Humanized anti-human CD19 antibodies and methods of use

The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) a polypeptide comprising three ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by peptide linkers and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.

Antigen binding molecules comprising a trimeric TNF family ligand and encoding polynucleotides thereof

The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target 511cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

T cell activating bispecific antigen binding molecules

The present invention generally relates to antibodies that bind to STEAP-1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Antibodies binding to STEAP-1

The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells comprising a common light chain. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

The present invention generally relates to antibodies that bind to HLA-A2/WT1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Antibodies binding to HLA-A2/WT1

The present invention generally relates to diagnostic assays using cell cultures, in particular to chimeric antigen receptor (CAR) expressing reporter cell assays to analyze samples, in particular patient samples, to diagnose cancer by quantifying the expression of tumor antigens and/or predicting clinical response to cancer immunotherapies. A further aspect of the present invention is to improve safety of e.g., cancer immunotherapies.

CAR-T reporter based diagnostic assays to detect tumor antigens in cancer patients

Growing community of inventors

Kreuzlingen, Switzerland

Ekkehard Moessner